Drug shortages and IRA inflation rebates: Considerations for CMS Marta E. Wosińska Thursday, February 9, 2023
Building resilience into US prescription drug supply chains Minje Park, Rena M. Conti, Marta E. Wosińska, Ergun Ozlem, Wallace J. Hopp, and Erin R. Fox Monday, January 30, 2023
Some drugs that improve price competition fall through the cracks of FDA user fees Marta E. Wosińska and Richard G. Frank Monday, December 12, 2022
Comments on the draft harmonized system code list of critical supply chains Marta E. Wosińska and Rena M. Conti Monday, November 7, 2022
2022 Sep 28 Past Event Recent trends in global value chains and beyond 9:00 AM - 11:10 AM EDT Washington, DC
Comments on the Request for Information on Medicare Loren Adler, Matthew Fiedler, Richard G. Frank, and Marta E. Wosińska Wednesday, September 7, 2022
The Senate’s plan on insulin drugs is the wrong way to solve the affordability problem Richard G. Frank and Marta E. Wosińska Thursday, July 7, 2022
To prevent public health crises, we need to update the essential medical product list Marta E. Wosińska and Richard G. Frank Friday, June 24, 2022
The FDA could do more to promote generic competition: Here’s how Rachel E. Sachs, Marta E. Wosińska, Richard G. Frank, and Loren Adler Tuesday, June 14, 2022
